GO
Loading...

Bullish on Biotechs

Wednesday, 4 Apr 2012 | 2:34 PM ET

Keryx Biopharma is down more than 70 percent after one of its colon cancer drugs failed a late stage clinical trial, with Mark Tepper, Strategic Wealth Partners managing partner.